VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
2023 E. Sajjadi, K. Venetis, M. Ivanova, M. Noale, C. Blundo, E. Di Loreto, G. Scarfone, S. Ferrero, S. Maggi, P. Veronesi, V.E. Galimberti, G. Viale, F.A. Peccatori, N. Fusco, E. Guerini-Rocco
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy
2022 S. Pece, I. Sestak, F. Montani, M. Tillhon, P. Maisonneuve, S. Freddi, K. Chu, M. Colleoni, P. Veronesi, D. Disalvatore, G. Viale, R. Buus, J. Cuzick, M. Dowsett, P.P. Di Fiore
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
2022 G. Bonizzi, M. Capra, C. Cassi, G. Taliento, O. Pala, E. Sajjadi, K. Venetis, M. Ivanova, M. Monturano, G. Renne, L. Zattoni, E. Guerini-Rocco, G. Viale, R. Orecchia, N. Fusco
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
2022 M. Garutti, G. Griguolo, A. Botticelli, G. Buzzatti, C. De Angelis, L. Gerratana, C. Molinelli, V. Adamo, G. Bianchini, L. Biganzoli, G. Curigliano, M. De Laurentiis, A. Fabi, A. Frassoldati, A. Gennari, C. Marchiò, F. Perrone, G. Viale, C. Zamagni, A. Zambelli, L. Del Mastro, S. De Placido, V. Guarneri, P. Marchetti, F. Puglisi
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2022 N. Bianco, M. Milano, E. Pagan, C. Oriecuia, V. Bagnardi, E.G. Rocco, G.I. Santomauro, G. Peruzzotti, M. Colleoni, G. Viale
Sex and cancer immunotherapy: Current understanding and challenges
2022 L. Pala, T. De Pas, C. Catania, G. Giaccone, A. Mantovani, S. Minucci, G. Viale, R.D. Gelber, F. Conforti
Standard operating procedures for biobank in oncology
2022 G. Bonizzi, L. Zattoni, M. Capra, C. Cassi, G. Taliento, M. Ivanova, E. Guerini-Rocco, M. Fumagalli, M. Monturano, A. Albini, G. Viale, R. Orecchia, N. Fusco
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
2022 J. Rüschoff, M. Friedrich, I. Nagelmeier, M. Kirchner, L.M. Andresen, K. Salomon, B. Portier, S.T. Sredni, H.U. Schildhaus, B. Jasani, M. Grzelinski, G. Viale
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis
2022 L. Pala, I. Sala, C. Oriecuia, T. De Pas, P. Queirolo, C. Specchia, E. Cocorocchio, P. Ferrucci, D. Patanè, M. Saponara, E. Pennacchioli, S. Coppola, G. Viale, G. Giaccone, R.D. Gelber, V. Bagnardi, F. Conforti
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features
2022 N. Fusco, E. Sajjadi, K. Venetis, M. Ivanova, S. Andaloro, E. Guerini-Rocco, E. Montagna, P. Caldarella, P. Veronesi, M. Colleoni, G. Viale
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
2022 L. Gianni, C.S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E.M. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa, G. Viale
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
2022 E. Montagna, E. Pagan, G. Cancello, C. Sangalli, V. Bagnardi, E. Munzone, E.O. Salè, D. Malengo, M.E. Cazzaniga, M. Negri, G. Peruzzotti, P. Veronesi, G. Viale, M. Colleoni
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
2022 S.S. Badve, F. Penault-Llorca, J.S. Reis-Filho, R. Deurloo, K.P. Siziopikou, C. D'Arrigo, G. Viale
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale